{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T11:00:57Z","timestamp":1784718057007,"version":"3.55.0"},"reference-count":92,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T00:00:00Z","timestamp":1784678400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T00:00:00Z","timestamp":1784678400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Heart Fail Rep"],"DOI":"10.1007\/s11897-026-00770-z","type":"journal-article","created":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T09:03:51Z","timestamp":1784711031000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Time to Personalize Surveillance for Cancer Therapy-Related Cardiac Dysfunction in HER2-Targeted Therapy: One Size Does Not Fit All"],"prefix":"10.1007","volume":"23","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7273-8352","authenticated-orcid":false,"given":"Sara","family":"Ebrahimi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-0864-3705","authenticated-orcid":false,"given":"Lalith Vardhan","family":"Namburu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6147-9591","authenticated-orcid":false,"given":"Anita","family":"Deswal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,22]]},"reference":[{"issue":"1","key":"770_CR1","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1186\/s44348-024-00014-5","volume":"32","author":"I Cho","year":"2024","unstructured":"Cho I, You S-C, Cha M-J, Hwang H-J, Cho EJ, Kim HJ, et al. Cancer therapy-related cardiac dysfunction and the role of cardiovascular imaging: systemic review and opinion paper from the Working Group on Cardio-Oncology of the Korean Society of Cardiology. J Cardiovasc Imaging. 2024;32(1):13.","journal-title":"J Cardiovasc Imaging"},{"key":"770_CR2","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1016\/j.amjcard.2024.08.029","volume":"231","author":"J Mallidi","year":"2024","unstructured":"Mallidi J, Baylis R, Song EJ. Management of Cancer Therapy\u2013Related Cardiac Dysfunction: A Case-Based Review. Am J Cardiol. 2024;231:20\u201331.","journal-title":"Am J Cardiol"},{"issue":"3","key":"770_CR3","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1016\/j.jjcc.2022.04.006","volume":"81","author":"M Oikawa","year":"2023","unstructured":"Oikawa M, Ishida T, Takeishi Y. Cancer therapeutics-related cardiovascular dysfunction: Basic mechanisms and clinical manifestation. J Cardiol. 2023;81(3):253\u20139.","journal-title":"J Cardiol"},{"issue":"12","key":"770_CR4","doi-asserted-by":"publisher","first-page":"2914","DOI":"10.3390\/biomedicines12122914","volume":"12","author":"P Theofilis","year":"2024","unstructured":"Theofilis P, Vlachakis PK, Oikonomou E, Drakopoulou M, Karakasis P, Apostolos A, et al. Cancer Therapy-Related Cardiac Dysfunction: A Review of Current Trends in Epidemiology, Diagnosis, and Treatment. Biomedicines. 2024;12(12):2914.","journal-title":"Biomedicines"},{"key":"770_CR5","doi-asserted-by":"publisher","DOI":"10.1177\/1179546819866445","volume":"13","author":"I-O Perez","year":"2019","unstructured":"Perez I-O, Taveras Alam S, Hernandez GA, Sancassani R. Cancer therapy-related cardiac dysfunction: an overview for the clinician. Clin Med Insights Cardiol. 2019;13:1179546819866445.","journal-title":"Clin Med Insights Cardiol"},{"key":"770_CR6","doi-asserted-by":"crossref","unstructured":"Eiger D, Franzoi MA, Pond\u00e9 N, Brand\u00e3o M, de Angelis C, Schmitt Nogueira M et al. Cardiotoxicity of trastuzumab given for 12 months compared to shorter treatment periods: a systematic review and meta-analysis of six clinical trials. ESMO Open. 2020;5(1).","DOI":"10.1136\/esmoopen-2019-000659"},{"key":"770_CR7","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2024.1479983","volume":"15","author":"Y Wang","year":"2024","unstructured":"Wang Y, Xu J, Xie Y, Zhou D, Guo M, Qin Y, et al. Interventions for prevention and treatment of trastuzumab-induced cardiotoxicity: an umbrella review of systematic reviews and meta-analyses. Front Pharmacol. 2024;15:1479983.","journal-title":"Front Pharmacol"},{"issue":"6","key":"770_CR8","doi-asserted-by":"publisher","first-page":"5073","DOI":"10.3390\/curroncol28060427","volume":"28","author":"S Dent","year":"2021","unstructured":"Dent S, Fergusson D, Aseyev O, Stober C, Pond G, Awan AA, et al. A randomized trial comparing 3- versus 4-monthly cardiac monitoring in patients receiving trastuzumab-based chemotherapy for early breast cancer. Curr Oncol. 2021;28(6):5073\u201383.","journal-title":"Curr Oncol"},{"issue":"4","key":"770_CR9","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1016\/j.jaccao.2025.05.006","volume":"7","author":"AF Yu","year":"2025","unstructured":"Yu AF, Dang CT, Moskowitz CS, Mishra Meza A, DeFusco P, Oligino E, et al. Cardiac safety of reduced cardiotoxicity surveillance during HER2-targeted therapy. JACC CardioOncology. 2025;7(4):430\u201341.","journal-title":"JACC CardioOncology"},{"issue":"41","key":"770_CR10","doi-asserted-by":"publisher","first-page":"4229","DOI":"10.1093\/eurheartj\/ehac244","volume":"43","author":"AR Lyon","year":"2022","unstructured":"Lyon AR, Fern\u00e1ndez T, Couch LS, Asteggiano R, Aznar MC, Bergler-Klei J, et al. 2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS). Eur Heart J. 2022;43(41):4229\u2013361.","journal-title":"Eur Heart J"},{"issue":"1","key":"770_CR11","first-page":"e002661","volume":"9","author":"MW Bloom","year":"2016","unstructured":"Bloom MW, Hamo CE, Cardinale D, Ky B, Nohria A, Baer L, et al. Cancer Therapy\u2013Related Cardiac Dysfunction and Heart Failure. Circulation: Heart Fail. 2016;9(1):e002661.","journal-title":"Circulation: Heart Fail"},{"key":"770_CR12","doi-asserted-by":"publisher","first-page":"e16","DOI":"10.15420\/ecr.2022.63","volume":"18","author":"DG Gent","year":"2023","unstructured":"Gent DG, Rebecca D. The 2022 European Society of Cardiology Cardio-oncology Guidelines in Focus. Eur Cardiol. 2023;18:e16.","journal-title":"Eur Cardiol"},{"issue":"3","key":"770_CR13","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1016\/j.jcmg.2022.10.010","volume":"16","author":"T Negishi","year":"2023","unstructured":"Negishi T, Thavendiranathan P, Penicka M, Lemieux J, Murbraech K, Miyazaki S, et al. Cardioprotection Using Strain-Guided Management of Potentially Cardiotoxic Cancer Therapy: 3-Year Results of the SUCCOUR Trial. JACC Cardiovasc Imaging. 2023;16(3):269\u201378.","journal-title":"JACC Cardiovasc Imaging"},{"issue":"41","key":"770_CR14","doi-asserted-by":"publisher","first-page":"4414","DOI":"10.1093\/eurheartj\/ehae574","volume":"45","author":"TH Marwick","year":"2024","unstructured":"Marwick TH, Dewar E, Nolan M, Shirazi M, Dias P, Wright L, et al. Strain surveillance during chemotherapy to improve cardiovascular outcomes: the SUCCOUR-MRI trial. Eur Heart J. 2024;45(41):4414\u201324.","journal-title":"Eur Heart J"},{"issue":"41","key":"770_CR15","doi-asserted-by":"publisher","first-page":"4425","DOI":"10.1093\/eurheartj\/ehae598","volume":"45","author":"A Barac","year":"2024","unstructured":"Barac A, Mauro L, Harnden K. From setbacks to success: building a promising path for strain-guided cardioprotection during anthracycline treatment. Eur Heart J. 2024;45(41):4425\u20137.","journal-title":"Eur Heart J"},{"issue":"22","key":"770_CR16","doi-asserted-by":"publisher","first-page":"1981","DOI":"10.1161\/CIRCULATIONAHA.114.013777","volume":"131","author":"D Cardinale","year":"2015","unstructured":"Cardinale D, Colombo A, Bacchiani G, Tedeschi I, Meroni CA, Veglia F, et al. Early Detection of Anthracycline Cardiotoxicity and Improvement With Heart Failure Therapy. Circulation. 2015;131(22):1981\u20138.","journal-title":"Circulation"},{"issue":"2","key":"770_CR17","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1016\/j.cardfail.2024.08.045","volume":"31","author":"MW Bloom","year":"2025","unstructured":"Bloom MW, Vo JB, Rodgers JE, Ferrari AM, Nohria A, Deswal A, et al. Cardio-Oncology and Heart Failure: a Scientific Statement From the Heart Failure Society of America. J Card Fail. 2025;31(2):415\u201355.","journal-title":"J Card Fail"},{"issue":"11","key":"770_CR18","doi-asserted-by":"publisher","first-page":"2869","DOI":"10.1002\/cncr.11407","volume":"97","author":"SM Swain","year":"2003","unstructured":"Swain SM, Whaley F, Ewer MS. Congestive heart failure in patients treated with doxorubicin: a retrospective analysis of three trials. Cancer. 2003;97(11):2869\u201379.","journal-title":"Cancer"},{"issue":"36","key":"770_CR19","doi-asserted-by":"publisher","first-page":"2768","DOI":"10.1093\/eurheartj\/ehw211","volume":"37","author":"J Zamorano","year":"2016","unstructured":"Zamorano J, Lancellotti P, Rodriguez Mu\u00f1oz D, Aboyans V, Asteggiano R, Galderisi M, et al. 2016 ESC position paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines: the Task Force for cancer treatments and cardiovascular toxicity of the European Society of Cardiology (ESC). Eur Heart J. 2016;37(36):2768\u2013801.","journal-title":"Eur Heart J"},{"issue":"4","key":"770_CR20","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1634\/theoncologist.2008-0230","volume":"14","author":"JS Ross","year":"2009","unstructured":"Ross JS, Slodkowska EA, Symmans WF, Pusztai L, Ravdin PM, Hortobagyi GN. The HER-2 receptor and breast cancer: ten years of targeted anti-HER-2 therapy and personalized medicine. Oncologist. 2009;14(4):320\u201368.","journal-title":"Oncologist"},{"issue":"1","key":"770_CR21","doi-asserted-by":"publisher","first-page":"18","DOI":"10.5858\/2007-131-18-ASOCCO","volume":"131","author":"AC Wolff","year":"2007","unstructured":"Wolff AC, Hammond ME, Schwartz JN, Hagerty KL, Allred DC, Cote RJ, et al. American Society of Clinical Oncology\/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. Arch Pathol Lab Med. 2007;131(1):18\u201343.","journal-title":"Arch Pathol Lab Med"},{"issue":"1","key":"770_CR22","first-page":"22","volume":"9","author":"H Eaton","year":"2023","unstructured":"Eaton H, Timm KN. Mechanisms of trastuzumab induced cardiotoxicity - is exercise a potential treatment? Cardiooncology. 2023;9(1):22.","journal-title":"Cardiooncology"},{"issue":"9","key":"770_CR23","doi-asserted-by":"publisher","first-page":"e006915","DOI":"10.1161\/JAHA.117.006915","volume":"6","author":"R Florido","year":"2017","unstructured":"Florido R, Smith KL, Cuomo KK, Russell SD. Cardiotoxicity From Human Epidermal Growth Factor Receptor-2 (HER2) Targeted Therapies. LID\u2009\u2013\u200910.1161\/JAHA.117.006915 [doi] LID - e006915 FAU - Florido, Roberta. J Am Heart Assoc. 2017;6(9):e006915.","journal-title":"J Am Heart Assoc"},{"issue":"11","key":"770_CR24","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1056\/NEJM200103153441101","volume":"344","author":"DJ Slamon","year":"2001","unstructured":"Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med. 2001;344(11):783\u201392.","journal-title":"N Engl J Med"},{"issue":"10","key":"770_CR25","doi-asserted-by":"publisher","first-page":"1030","DOI":"10.1200\/JCO.2015.64.5515","volume":"34","author":"CT Dang","year":"2016","unstructured":"Dang CT, Yu AF, Jones LW, Liu J, Steingart RM, Argolo DF, et al. Cardiac Surveillance Guidelines for Trastuzumab-Containing Therapy in Early-Stage Breast Cancer: Getting to the Heart of the Matter. J Clin Oncol. 2016;34(10):1030\u20133.","journal-title":"J Clin Oncol"},{"key":"770_CR26","unstructured":"HERCEPTIN\u00ae (trastuzumab) for injection, for intravenous use: U.S. Food and Drug Administration; 2024 updated 6\/18\/2024. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2024\/103792s5354lbl.pdf. Access date 1 May 2026."},{"issue":"20","key":"770_CR27","doi-asserted-by":"publisher","first-page":"2159","DOI":"10.1200\/JCO.2013.53.9288","volume":"32","author":"E de Azambuja","year":"2014","unstructured":"de Azambuja E, Procter MJ, van Veldhuisen DJ, Agbor-Tarh D, Metzger-Filho O, Steinseifer J, et al. Trastuzumab-associated cardiac events at 8 years of median follow-up in the Herceptin Adjuvant trial (BIG 1\u201301). J Clin Oncol. 2014;32(20):2159\u201365.","journal-title":"J Clin Oncol"},{"issue":"8","key":"770_CR28","doi-asserted-by":"publisher","first-page":"e30","DOI":"10.1161\/CIR.0000000000000556","volume":"137","author":"LS Mehta","year":"2018","unstructured":"Mehta LS, Watson KE, Barac A, Beckie TM, Bittner V, Cruz-Flores S, et al. Cardiovascular Disease and Breast Cancer: Where These Entities Intersect: A Scientific Statement From the American Heart Association. Circulation. 2018;137(8):e30\u201366.","journal-title":"Circulation"},{"issue":"1","key":"770_CR29","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-022-18342-1","volume":"12","author":"L Zhang","year":"2022","unstructured":"Zhang L, Wang Y, Meng W, Zhao W, Tong Z. Cardiac safety analysis of anti-HER2-targeted therapy in early breast cancer. Sci Rep. 2022;12(1):14312.","journal-title":"Sci Rep"},{"issue":"9","key":"770_CR30","doi-asserted-by":"publisher","first-page":"2278","DOI":"10.1093\/annonc\/mdt182","volume":"24","author":"A Schneeweiss","year":"2013","unstructured":"Schneeweiss A, Chia S, Hickish T, Harvey V, Eniu A, Hegg R, et al. Pertuzumab plus trastuzumab in combination with standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer: a randomized phase II cardiac safety study (TRYPHAENA). Ann Oncol. 2013;24(9):2278\u201384.","journal-title":"Ann Oncol"},{"issue":"11","key":"770_CR31","doi-asserted-by":"publisher","first-page":"2596","DOI":"10.3390\/cancers14112596","volume":"14","author":"C Dang","year":"2022","unstructured":"Dang C, Ewer MS, Delaloge S, Ferrero J-M, Colomer R, de la Cruz-Merino L, et al. BERENICE Final Analysis: Cardiac Safety Study of Neoadjuvant Pertuzumab, Trastuzumab, and Chemotherapy Followed by Adjuvant Pertuzumab and Trastuzumab in HER2-Positive Early Breast Cancer. Cancers. 2022;14(11):2596.","journal-title":"Cancers"},{"issue":"1","key":"770_CR32","doi-asserted-by":"publisher","first-page":"100772","DOI":"10.1016\/j.esmoop.2022.100772","volume":"8","author":"E de Azambuja","year":"2023","unstructured":"de Azambuja E, Agostinetto E, Procter M, Eiger D, Pond\u00e9 N, Guillaume S, et al. Cardiac safety of dual anti-HER2 blockade with pertuzumab plus trastuzumab in early HER2-positive breast cancer in the APHINITY trial\u2606. ESMO Open. 2023;8(1):100772.","journal-title":"ESMO Open"},{"issue":"4","key":"770_CR33","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1016\/S1470-2045(19)30863-0","volume":"21","author":"SM Swain","year":"2020","unstructured":"Swain SM, Miles D, Kim SB, Im YH, Im SA, Semiglazov V, et al. Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA): end-of-study results from a double-blind, randomised, placebo-controlled, phase 3 study. Lancet Oncol. 2020;21(4):519\u201330.","journal-title":"Lancet Oncol"},{"issue":"10","key":"770_CR34","doi-asserted-by":"publisher","first-page":"1034","DOI":"10.1200\/JCO.2015.62.1797","volume":"34","author":"M Piccart-Gebhart","year":"2016","unstructured":"Piccart-Gebhart M, Holmes E, Baselga J, de Azambuja E, Dueck AC, Viale G, et al. Adjuvant lapatinib and trastuzumab for early human epidermal growth factor receptor 2-positive breast cancer: results from the randomized phase III adjuvant lapatinib and\/or trastuzumab treatment optimization trial. J Clin Oncol. 2016;34(10):1034\u201342.","journal-title":"J Clin Oncol"},{"issue":"11","key":"770_CR35","doi-asserted-by":"publisher","first-page":"e2540336","DOI":"10.1001\/jamanetworkopen.2025.40336","volume":"8","author":"L Seth","year":"2025","unstructured":"Seth L, Bhave A, Kollapaneni S, Shah V, Nahle T, Blaes A, et al. Cardiotoxic Effects of Antibody Drug Conjugates vs Standard Chemotherapy in ERBB2-Positive Advanced Breast Cancer: A Systematic Review and Meta-Analysis. JAMA Netw Open. 2025;8(11):e2540336\u2013e.","journal-title":"JAMA Netw Open"},{"issue":"4","key":"770_CR36","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1177\/2042098614529603","volume":"5","author":"AA Onitilo","year":"2014","unstructured":"Onitilo AA, Engel JM, Stankowski RV. Cardiovascular toxicity associated with adjuvant trastuzumab therapy: prevalence, patient characteristics, and risk factors. Ther Adv Drug Saf. 2014;5(4):154\u201366.","journal-title":"Ther Adv Drug Saf"},{"issue":"3","key":"770_CR37","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1016\/j.jaccao.2024.12.007","volume":"7","author":"A Ali","year":"2025","unstructured":"Ali A, Koutroumpakis E, Song J, Booser D, Barcenas CH, Tripathy D, et al. Risk stratification for trastuzumab-induced cardiac dysfunction and potential implications for surveillance. JACC CardioOncology. 2025;7(3):203\u201315.","journal-title":"JACC CardioOncology"},{"issue":"1","key":"770_CR38","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1200\/JCO.23.01779","volume":"43","author":"G Bostany","year":"2025","unstructured":"Bostany G, Chen Y, Francisco L, Dai C, Meng Q, Sparks J, et al. Cardiac Dysfunction Among Breast Cancer Survivors: Role of Cardiotoxic Therapy and Cardiovascular Risk Factors. J Clin Oncol. 2025;43(1):32\u201345.","journal-title":"J Clin Oncol"},{"key":"770_CR39","doi-asserted-by":"crossref","unstructured":"Seidman A, Hudis C Fau - Pierri MK, Pierri Mk Fau - Shak S, Shak S Fau - Paton V,Paton V Fau - Ashby M, Ashby M Fau - Murphy M, et al. Cardiac dysfunction in the trastuzumab clinical trials experience. J Clin Oncol. 2002;20(5):1215-21.","DOI":"10.1200\/JCO.2002.20.5.1215"},{"issue":"8","key":"770_CR40","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1200\/JCO.2016.70.5400","volume":"35","author":"SH Armenian","year":"2016","unstructured":"Armenian SH, Lacchetti C, Barac A, Carver J, Constine LS, Denduluri N, et al. Prevention and Monitoring of Cardiac Dysfunction in Survivors of Adult Cancers: American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol. 2016;35(8):893\u2013911.","journal-title":"J Clin Oncol"},{"issue":"2","key":"770_CR41","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1016\/j.annonc.2019.10.023","volume":"31","author":"G Curigliano","year":"2020","unstructured":"Curigliano G, Lenihan D, Fradley M, Ganatra S, Barac A, Blaes A, et al. Management of cardiac disease in cancer patients throughout oncological treatment: ESMO consensus recommendations. Ann Oncol. 2020;31(2):171\u201390.","journal-title":"Ann Oncol"},{"key":"770_CR42","unstructured":"PERJETA\u00ae. (pertuzumab) Injection, for intravenous use: U.S. Food and Drug Administration; 2012 updated 9\/2013. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2013\/125409s051lbl.pdf. Access date 1 May 2026."},{"key":"770_CR43","unstructured":"MARGENZATM (margetuximab-. cmkb) injection, for intravenous use U.S. Food and Drug Administration; 2020 updated 12\/2020. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2020\/761150s000lbl.pdf. Access date 1 May 2026."},{"key":"770_CR44","unstructured":"KADCYLA\u00ae (ado-trastuzumab emtansine) for injection, for intravenous use: U.S. Food and Drug Administration. 2013 updated 5\/2025. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2025\/125427s121lbl.pdf. Access date\u00a01 May 2026."},{"key":"770_CR45","unstructured":"ENHERTU\u00ae (fam-trastuzumab. deruxtecan-nxki) for injection, for intravenous use: U.S. Food and Drug Administration; 2019 updated 4\/2024. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2024\/761139s028lbl.pdf. Access date 1 May 2026."},{"issue":"11","key":"770_CR46","doi-asserted-by":"publisher","first-page":"1945","DOI":"10.1002\/ejhf.1920","volume":"22","author":"AR Lyon","year":"2020","unstructured":"Lyon AR, Dent S, Stanway S, Earl H, Brezden-Masley C, Cohen-Solal A, et al. Baseline cardiovascular risk assessment in cancer patients scheduled to receive cardiotoxic cancer therapies: a position statement and new risk assessment tools from the Cardio-Oncology Study Group of the Heart Failure Association of the European Society of Cardiology in collaboration with the International Cardio-Oncology Society. Eur J Heart Fail. 2020;22(11):1945\u201360.","journal-title":"Eur J Heart Fail"},{"key":"770_CR47","doi-asserted-by":"publisher","first-page":"e084062","DOI":"10.1136\/bmj-2025-084062","volume":"390","author":"C Gomes","year":"2025","unstructured":"Gomes C, Geels J, Debray TPA, Malekzadeh A, Asselbergs FW, Linschoten M. Risk prediction models for cancer therapy related cardiac dysfunction in patients with cancer and cancer survivors: systematic review and meta-analysis. BMJ. 2025;390:e084062.","journal-title":"BMJ"},{"key":"770_CR48","doi-asserted-by":"crossref","unstructured":"Suntheralingam S, Fan CS, Calvillo-Arg\u00fcelles O, Abdel-Qadir H, Amir E, Thavendiranathan P. Evaluation of Risk Prediction Models to Identify Cancer Therapeutics Related Cardiac Dysfunction in Women with HER2\u2009+\u2009Breast Cancer. J Clin Med. 2022;11(3).","DOI":"10.3390\/jcm11030847"},{"issue":"1","key":"770_CR49","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1007\/s10549-021-06192-w","volume":"188","author":"NML Battisti","year":"2021","unstructured":"Battisti NML, Andres MS, Lee KA, Ramalingam S, Nash T, Mappouridou S, et al. Incidence of cardiotoxicity and validation of the Heart Failure Association-International Cardio-Oncology Society risk stratification tool in patients treated with trastuzumab for HER2-positive early breast cancer. Breast Cancer Res Treat. 2021;188(1):149\u201363.","journal-title":"Breast Cancer Res Treat"},{"key":"770_CR50","doi-asserted-by":"crossref","unstructured":"Cronin M, Crowley A, Davey MG, Ryan P, Abdelshafy M, Elkoumy A et al. Heart Failure Association-International Cardio-Oncology Society Risk Score Validation in HER2-Positive Breast Cancer. J Clin Med. 2023;12(4).","DOI":"10.3390\/jcm12041278"},{"issue":"1","key":"770_CR51","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.clbc.2022.10.010","volume":"23","author":"X Liu","year":"2023","unstructured":"Liu X, Tao L, Wang M, Li H, Xu W. ABSDELL Model: Development and Internal Validation of a Risk Prediction Model of LVEF Decline in Breast Cancer Patients Treated With Trastuzumab. Clin Breast Cancer. 2023;23(1):23\u201331.","journal-title":"Clin Breast Cancer"},{"issue":"19","key":"770_CR52","doi-asserted-by":"publisher","first-page":"e029465","DOI":"10.1161\/JAHA.123.029465","volume":"12","author":"AF Yu","year":"2023","unstructured":"Yu AF, Lin IH, Jorgensen J, Copeland-Halperin R, Feldman S, Ibtida I, et al. Nomogram for Predicting Risk of Cancer Therapy-Related Cardiac Dysfunction in Patients With Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer. J Am Heart Assoc. 2023;12(19):e029465.","journal-title":"J Am Heart Assoc"},{"issue":"16","key":"770_CR53","doi-asserted-by":"publisher","first-page":"e021931","DOI":"10.1161\/JAHA.121.021931","volume":"10","author":"DY Kim","year":"2021","unstructured":"Kim DY, Park MS, Youn JC, Lee S, Choi JH, Jung MH, et al. Development and Validation of a Risk Score Model for Predicting the Cardiovascular Outcomes After Breast Cancer Therapy: The CHEMO-RADIAT Score. J Am Heart Assoc. 2021;10(16):e021931.","journal-title":"J Am Heart Assoc"},{"issue":"10","key":"770_CR54","doi-asserted-by":"publisher","first-page":"2731","DOI":"10.1007\/s00204-022-03341-y","volume":"96","author":"WT Chang","year":"2022","unstructured":"Chang WT, Liu CF, Feng YH, Liao CT, Wang JJ, Chen ZC, et al. An artificial intelligence approach for predicting cardiotoxicity in breast cancer patients receiving anthracycline. Arch Toxicol. 2022;96(10):2731\u20137.","journal-title":"Arch Toxicol"},{"key":"770_CR55","doi-asserted-by":"crossref","unstructured":"Barac A, Chou J, Shara N, Chen LH, Shi J, Chlebowski RT et al. Risk Prediction Model for Development of Heart Failure or Cardiomyopathy After Breast Cancer Treatment. JAMA Oncol. 2025.","DOI":"10.1001\/jamaoncol.2025.4178"},{"issue":"18","key":"770_CR56","doi-asserted-by":"publisher","first-page":"2232","DOI":"10.1200\/JCO.2011.40.1273","volume":"30","author":"SH Giordano","year":"2012","unstructured":"Giordano SH, Lin YL, Kuo YF, Hortobagyi GN, Goodwin JS. Decline in the use of anthracyclines for breast cancer. J Clin Oncol. 2012;30(18):2232\u20139.","journal-title":"J Clin Oncol"},{"issue":"1","key":"770_CR57","first-page":"1","volume":"4","author":"C Glen","year":"2022","unstructured":"Glen C, Tan YY, Waterston A, Evans TRJ, Jones RJ, Petrie MC, et al. Mechanistic and Clinical Overview Cardiovascular Toxicity of BRAF and MEK Inhibitors: JACC: CardioOncology State-of-the-Art Review. JACC: CardioOncology. 2022;4(1):1\u201318.","journal-title":"JACC: CardioOncology"},{"key":"770_CR58","unstructured":"MEKINIST\u00ae (trametinib) tablets, for oral use: U.S. Food and Drug Administration. 2013 updated 6\/2022. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2022\/204114s024lbl.pdf. Access date 1 May 2026."},{"issue":"7","key":"770_CR59","first-page":"852","volume":"7","author":"C Glen","year":"2025","unstructured":"Glen C, Dobbin SJH, Mangion K, Henderson A, Brooksbank K, Coats CJ, et al. Prospective Evaluation of the Cardiovascular Effects of BRAF and MEK Inhibitors in Patients With Melanoma. JACC: CardioOncology. 2025;7(7):852\u201366.","journal-title":"JACC: CardioOncology"},{"issue":"1","key":"770_CR60","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jaccao.2022.01.096","volume":"4","author":"C Glen","year":"2022","unstructured":"Glen C, Tan YY, Waterston A, Evans TRJ, Jones RJ, Petrie MC, et al. Mechanistic and Clinical Overview Cardiovascular Toxicity of BRAF and MEK Inhibitors: JACC: CardioOncology State-of-the-Art Review. JACC CardioOncol. 2022;4(1):1\u201318.","journal-title":"JACC CardioOncol"},{"issue":"6","key":"770_CR61","doi-asserted-by":"publisher","first-page":"1109","DOI":"10.1016\/0002-9343(87)90212-9","volume":"82","author":"RG Schwartz","year":"1987","unstructured":"Schwartz RG, McKenzie WB, Alexander J, Sager P, D\u2019Souza A, Manatunga A, et al. Congestive heart failure and left ventricular dysfunction complicating doxorubicin therapy: Seven-year experience using serial radionuclide angiocardiography. Am J Med. 1987;82(6):1109\u201318.","journal-title":"Am J Med"},{"issue":"16","key":"770_CR62","doi-asserted-by":"publisher","first-page":"1659","DOI":"10.1056\/NEJMoa052306","volume":"353","author":"MJ Piccart-Gebhart","year":"2005","unstructured":"Piccart-Gebhart MJ, Procter M, Leyland-Jones B, Goldhirsch A, Untch M, Smith I, et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med. 2005;353(16):1659\u201372.","journal-title":"N Engl J Med"},{"issue":"14","key":"770_CR63","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.1056\/NEJMoa0910383","volume":"365","author":"D Slamon","year":"2011","unstructured":"Slamon D, Eiermann W, Robert N, Pienkowski T, Martin M, Press M, et al. Adjuvant Trastuzumab in HER2-Positive Breast Cancer. N Engl J Med. 2011;365(14):1273\u201383.","journal-title":"N Engl J Med"},{"key":"770_CR64","unstructured":"Common Terminology Criteria for Adverse Events (CTCAE). v6.0 (MedDRA 28.0): U.S. Department of Health and Human Services; 2025 updated 7\/22\/2025. Available from: https:\/\/dctd.cancer.gov\/research\/ctep-trials\/for-sites\/adverse-events\/ctcae-v6.pdf. Access date 1 May 2026."},{"key":"770_CR65","unstructured":"Common Terminology Criteria for Adverse Events. (CTCAE) Version 5.0: U.S. Department of Health and Human Services; 2017 updated 11\/27\/2017. Available from: https:\/\/dctd.cancer.gov\/research\/ctep-trials\/for-sites\/adverse-events\/ctcae-v5-5x7.pdf. Access date\u00a01 May 2026."},{"issue":"5","key":"770_CR66","doi-asserted-by":"publisher","first-page":"1215","DOI":"10.1200\/JCO.2002.20.5.1215","volume":"20","author":"A Seidman","year":"2002","unstructured":"Seidman A, Hudis C, Pierri MK, Shak S, Paton V, Ashby M, et al. Cardiac dysfunction in the trastuzumab clinical trials experience. J Clin Oncol. 2002;20(5):1215\u201321.","journal-title":"J Clin Oncol"},{"issue":"10","key":"770_CR67","doi-asserted-by":"publisher","first-page":"1063","DOI":"10.1093\/ehjci\/jeu192","volume":"15","author":"JC Plana","year":"2014","unstructured":"Plana JC, Galderisi M, Barac A, Ewer MS, Ky B, Scherrer-Crosbie M, et al. Expert consensus for multimodality imaging evaluation of adult patients during and after cancer therapy: a report from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. Eur Heart Journal\u2013Cardiovascular Imaging. 2014;15(10):1063\u201393.","journal-title":"Eur Heart Journal\u2013Cardiovascular Imaging"},{"issue":"31","key":"770_CR68","doi-asserted-by":"publisher","first-page":"7811","DOI":"10.1200\/JCO.2005.02.4091","volume":"23","author":"E Tan-Chiu","year":"2005","unstructured":"Tan-Chiu E, Yothers G, Romond E, Geyer CE, Ewer M, Keefe D, et al. Assessment of cardiac dysfunction in a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel, with or without trastuzumab as adjuvant therapy in node-positive, human epidermal growth factor receptor 2\u2013overexpressing breast cancer: NSABP B-31. J Clin Oncol. 2005;23(31):7811\u20139.","journal-title":"J Clin Oncol"},{"issue":"16","key":"770_CR69","doi-asserted-by":"publisher","first-page":"1673","DOI":"10.1056\/NEJMoa052122","volume":"353","author":"EH Romond","year":"2005","unstructured":"Romond EH, Perez EA, Bryant J, Suman VJ, Geyer CE, Davidson NE, et al. Trastuzumab plus Adjuvant Chemotherapy for Operable HER2-Positive Breast Cancer. N Engl J Med. 2005;353(16):1673\u201384.","journal-title":"N Engl J Med"},{"issue":"19","key":"770_CR70","doi-asserted-by":"publisher","first-page":"1783","DOI":"10.1056\/NEJMoa1209124","volume":"367","author":"S Verma","year":"2012","unstructured":"Verma S, Miles D, Gianni L, Krop IE, Welslau M, Baselga J, et al. Trastuzumab Emtansine for HER2-Positive Advanced Breast Cancer. N Engl J Med. 2012;367(19):1783\u201391.","journal-title":"N Engl J Med"},{"issue":"2","key":"770_CR71","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1056\/NEJMoa1406281","volume":"372","author":"SM Tolaney","year":"2015","unstructured":"Tolaney SM, Barry WT, Dang CT, Yardley DA, Moy B, Marcom PK, et al. Adjuvant paclitaxel and trastuzumab for node-negative, HER2-positive breast cancer. N Engl J Med. 2015;372(2):134\u201341.","journal-title":"N Engl J Med"},{"issue":"2","key":"770_CR72","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1200\/JCO.2016.67.4887","volume":"35","author":"EA Perez","year":"2017","unstructured":"Perez EA, Barrios C, Eiermann W, Toi M, Im Y-H, Conte P, et al. Trastuzumab emtansine with or without pertuzumab versus trastuzumab plus taxane for human epidermal growth factor receptor 2\u2013positive, advanced breast cancer: primary results from the phase III MARIANNE study. J Clin Oncol. 2017;35(2):141\u20138.","journal-title":"J Clin Oncol"},{"issue":"6","key":"770_CR73","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1016\/S1470-2045(17)30313-3","volume":"18","author":"IE Krop","year":"2017","unstructured":"Krop IE, Kim S-B, Martin AG, LoRusso PM, Ferrero J-M, Badovinac-Crnjevic T, et al. Trastuzumab emtansine versus treatment of physician\u2019s choice in patients with previously treated HER2-positive metastatic breast cancer (TH3RESA): final overall survival results from a randomised open-label phase 3 trial. Lancet Oncol. 2017;18(6):743\u201354.","journal-title":"Lancet Oncol"},{"issue":"7","key":"770_CR74","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1056\/NEJMoa1814017","volume":"380","author":"G von Minckwitz","year":"2019","unstructured":"von Minckwitz G, Huang C-S, Mano MS, Loibl S, Mamounas EP, Untch M, et al. Trastuzumab emtansine for residual invasive HER2-positive breast cancer. N Engl J Med. 2019;380(7):617\u201328.","journal-title":"N Engl J Med"},{"issue":"10191","key":"770_CR75","doi-asserted-by":"publisher","first-page":"2599","DOI":"10.1016\/S0140-6736(19)30650-6","volume":"393","author":"HM Earl","year":"2019","unstructured":"Earl HM, Hiller L, Vallier AL, Loi S, McAdam K, Hughes-Davies L, et al. 6 versus 12 months of adjuvant trastuzumab for HER2-positive early breast cancer (PERSEPHONE): 4-year disease-free survival results of a randomised phase 3 non-inferiority trial. Lancet. 2019;393(10191):2599\u2013612.","journal-title":"Lancet"},{"issue":"7","key":"770_CR76","doi-asserted-by":"publisher","first-page":"610","DOI":"10.1056\/NEJMoa1914510","volume":"382","author":"S Modi","year":"2020","unstructured":"Modi S, Saura C, Yamashita T, Park YH, Kim S-B, Tamura K, et al. Trastuzumab deruxtecan in previously treated HER2-positive breast cancer. N Engl J Med. 2020;382(7):610\u201321.","journal-title":"N Engl J Med"},{"issue":"3","key":"770_CR77","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1007\/s40264-019-00886-3","volume":"43","author":"HC Kolberg","year":"2020","unstructured":"Kolberg HC, Colleoni M, Demetriou GS, Santi P, Tesch H, Fujiwara Y, et al. Cardiac safety of the trastuzumab biosimilar ABP 980 in women with HER2-positive early breast cancer in the randomized, double-blind, active-controlled LILAC study. Drug Saf. 2020;43(3):233\u201342.","journal-title":"Drug Saf"},{"issue":"10","key":"770_CR78","doi-asserted-by":"publisher","first-page":"1453","DOI":"10.1038\/s41416-020-0786-x","volume":"122","author":"D Eiger","year":"2020","unstructured":"Eiger D, Pond\u00e9 NF, Agbor-Tarh D, Moreno-Aspitia A, Piccart M, Hilbers FS, et al. Long-term cardiac outcomes of patients with HER2-positive breast cancer treated in the adjuvant lapatinib and\/or trastuzumab treatment optimization trial. Br J Cancer. 2020;122(10):1453\u201360.","journal-title":"Br J Cancer"},{"issue":"7","key":"770_CR79","doi-asserted-by":"publisher","first-page":"978","DOI":"10.1001\/jamaoncol.2021.1371","volume":"7","author":"A van der Voort","year":"2021","unstructured":"van der Voort A, van Ramshorst MS, van Werkhoven ED, Mandjes IA, Kemper I, Vulink AJ, et al. Three-year follow-up of neoadjuvant chemotherapy with or without anthracyclines in the presence of dual ERBB2 blockade in patients with ERBB2-positive breast cancer: a secondary analysis of the TRAIN-2 randomized, phase 3 trial. JAMA Oncol. 2021;7(7):978\u201384.","journal-title":"JAMA Oncol"},{"issue":"4","key":"770_CR80","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1001\/jamaoncol.2020.7932","volume":"7","author":"HS Rugo","year":"2021","unstructured":"Rugo HS, Im S-A, Cardoso F, Cort\u00e9s J, Curigliano G, Musolino A, et al. Efficacy of Margetuximab vs Trastuzumab in Patients With Pretreated ERBB2-Positive Advanced Breast Cancer: A Phase 3 Randomized Clinical Trial. JAMA Oncol. 2021;7(4):573\u201384.","journal-title":"JAMA Oncol"},{"issue":"10390","key":"770_CR81","doi-asserted-by":"publisher","first-page":"1773","DOI":"10.1016\/S0140-6736(23)00725-0","volume":"401","author":"F Andr\u00e9","year":"2023","unstructured":"Andr\u00e9 F, Hee Park Y, Kim SB, Takano T, Im SA, Borges G, et al. Trastuzumab deruxtecan versus treatment of physician\u2019s choice in patients with HER2-positive metastatic breast cancer (DESTINY-Breast02): a randomised, open-label, multicentre, phase 3 trial. Lancet. 2023;401(10390):1773\u201385.","journal-title":"Lancet"},{"issue":"8","key":"770_CR82","doi-asserted-by":"publisher","first-page":"2208","DOI":"10.1038\/s41591-024-03021-7","volume":"30","author":"J Cort\u00e9s","year":"2024","unstructured":"Cort\u00e9s J, Hurvitz SA, Im S-A, Iwata H, Curigliano G, Kim S-B, et al. Trastuzumab deruxtecan versus trastuzumab emtansine in HER2-positive metastatic breast cancer: long-term survival analysis of the DESTINY-Breast03 trial. Nat Med. 2024;30(8):2208\u201315.","journal-title":"Nat Med"},{"issue":"12","key":"770_CR83","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1002989","volume":"16","author":"EG Kabor\u00e9","year":"2019","unstructured":"Kabor\u00e9 EG, Guenancia C-O, Vaz-Luis I, Di Meglio A-O, Pistilli B-O, Coutant C, et al. Association of body mass index and cardiotoxicity related to anthracyclines and trastuzumab in early breast cancer: French CANTO cohort study. PLoS Med. 2019;16(12):e1002989.","journal-title":"PLoS Med"},{"issue":"2","key":"770_CR84","first-page":"727","volume":"51","author":"EK Kim","year":"2019","unstructured":"Kim EK, Cho J, Kim JY, Chang SA, Park SJ, Choi JO, et al. Early Decline in Left Ventricular Ejection Fraction Can Predict Trastuzumab-Related Cardiotoxicity in Patients with Breast Cancer: A Study Using 13. Years Registry Data. 2019;51(2):727\u201336.","journal-title":"Years Registry Data"},{"issue":"2","key":"770_CR85","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1007\/s10549-020-05703-5","volume":"182","author":"H Cho","year":"2020","unstructured":"Cho H, Lee S, Sim SH, Park IH, Lee KS, Kwak MH, et al. Cumulative incidence of chemotherapy-induced cardiotoxicity during a 2-year follow-up period in breast cancer patients. Breast Cancer Res Treat. 2020;182(2):333\u201343.","journal-title":"Breast Cancer Res Treat"},{"key":"770_CR86","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1016\/j.breast.2021.03.004","volume":"57","author":"R De Sanctis","year":"2021","unstructured":"De Sanctis R, Giordano L, D\u2019Antonio F, Agostinetto E, Marinello A, Guiducci D, et al. Clinical predictors of cardiac toxicity in HER2-positive early breast cancer patients treated with adjuvant s.c. versus i.v. trastuzumab. Breast. 2021;57:80\u20135.","journal-title":"Breast"},{"issue":"12","key":"770_CR87","doi-asserted-by":"publisher","DOI":"10.1177\/03000605211053755","volume":"49","author":"A Acibuca","year":"2021","unstructured":"Acibuca A, Sezer A, Yilmaz M, Sumbul AT, Demircan S, Muderrisoglu IH, et al. Cardiotoxicity of trastuzumab emtansine (T-DM1): a single-center experience. J Int Med Res. 2021;49(12):3000605211053755.","journal-title":"J Int Med Res"},{"issue":"3","key":"770_CR88","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1007\/s10549-020-06039-w","volume":"186","author":"NA-O Bouwer","year":"2021","unstructured":"Bouwer NA-O, Steenbruggen TG, van Rosmalen J, Rier HN, Kitzen J, van Bekkum ML, et al. Cardiotoxicity during long-term trastuzumab use in patients with HER2-positive metastatic breast cancer: who needs cardiac monitoring? Breast Cancer Res Treat. 2021;186(3):851\u201362.","journal-title":"Breast Cancer Res Treat"},{"issue":"30","key":"770_CR89","doi-asserted-by":"publisher","first-page":"e29927","DOI":"10.1097\/MD.0000000000029927","volume":"101","author":"C Castillo","year":"2022","unstructured":"Castillo C, Camejo N, Etcheverria C, Ferradaz J, Ferreira A, Fontan A, et al. Trastuzumab-induced cardiotoxicity in early breast cancer over a 10-year period in Uruguay. Medicine. 2022;101(30):e29927.","journal-title":"Medicine"},{"key":"770_CR90","doi-asserted-by":"publisher","first-page":"103612","DOI":"10.1016\/j.breast.2023.103612","volume":"73","author":"KK Bao","year":"2024","unstructured":"Bao KK, Chan JC, Chan JG, Sutanto L, Cheung KM, Yiu HH. Real-world impact of dual anti-HER2 antibodies on cardiac function in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer. Breast. 2024;73:103612.","journal-title":"Breast"},{"issue":"1","key":"770_CR91","first-page":"68","volume":"10","author":"A Vaynrub","year":"2024","unstructured":"Vaynrub A, Mishalani L, Raikhelkar J, Crew KD. Predictors of trastuzumab-induced cardiotoxicity among racially and ethnically diverse patients with HER2-positive breast cancer. Cardiooncology. 2024;10(1):68.","journal-title":"Cardiooncology"},{"key":"770_CR92","doi-asserted-by":"publisher","first-page":"6505","DOI":"10.2147\/DDDT.S516457","volume":"19","author":"F Ju","year":"2025","unstructured":"Ju F, Gu H, Yu L, Zhao G, Liu Y, Yin D, et al. Analysis of cardiotoxicity and risk factors of breast cancer chemotherapy drugs: a five-year single-centre retrospective study in early breast cancer. Drug Des Devel Ther. 2025;19:6505\u201317.","journal-title":"Drug Des Devel Ther"}],"container-title":["Current Heart Failure Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11897-026-00770-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11897-026-00770-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11897-026-00770-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T10:02:17Z","timestamp":1784714537000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11897-026-00770-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,22]]},"references-count":92,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["770"],"URL":"https:\/\/doi.org\/10.1007\/s11897-026-00770-z","relation":{},"ISSN":["1546-9549"],"issn-type":[{"value":"1546-9549","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,22]]},"assertion":[{"value":"16 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"No animal or human subjects by the authors were used in this study.","order":1,"name":"Ethics","label":"Human and Animal Rights and Informed Consent","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"37"}}